login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
BIOMEA FUSION INC (BMEA) Stock News
USA
-
Nasdaq
- NASDAQ:BMEA -
US09077A1060
-
Common Stock
0.982
USD
-0.02 (-1.8%)
Last: 11/21/2025, 8:14:10 PM
1
USD
+0.02 (+1.83%)
After Hours:
11/21/2025, 8:14:10 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
BMEA Latest News, Press Relases and Analysis
All
Press Releases
12 days ago - By: Biomea Fusion, Inc.
Biomea Fusion to Participate at Jefferies London Healthcare Conference
17 days ago - By: Biomea Fusion, Inc.
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
17 days ago - By: Biomea Fusion, Inc.
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
18 days ago - By: Biomea Fusion, Inc.
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
18 days ago - By: Biomea Fusion, Inc.
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
23 days ago - By: Biomea Fusion, Inc.
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
23 days ago - By: Biomea Fusion, Inc.
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
a month ago - By: Biomea Fusion, Inc.
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
a month ago - By: Biomea Fusion, Inc.
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
a month ago - By: Biomea Fusion, Inc.
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
2 months ago - By: Benzinga
- Mentions:
SNWV
CLRB
APVO
SPRB
...
12 Health Care Stocks Moving In Tuesday's Intraday Session
2 months ago - By: Benzinga
Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study
2 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Announces Pricing of Public Offering of Securities
2 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Announces Pricing of Public Offering of Securities
2 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Announces Proposed Public Offering of Securities
2 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Announces Proposed Public Offering of Securities
2 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
2 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
2 months ago - By: Biomea Fusion, Inc.
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Biomea Fusion, Inc.
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
2 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
3 months ago - By: Yahoo Finance
- Mentions:
UBS
WYNN
DB
TIC
...
Five Below upgraded, Bill downgraded: Wall Street's top analyst calls
4 months ago - By: The Motley Fool
Biomea Fusion (BMEA) Q2 Loss Drops 44%
4 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
4 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
4 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Appoints Julianne Averill to its Board of Directors
4 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Appoints Julianne Averill to its Board of Directors
5 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
5 months ago - By: Biomea Fusion, Inc.
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Please enable JavaScript to continue using this application.